Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Cancer Clinical Trial

Official title:

An Open-label, Multicenter, Phase II Study of Capmatinib in Patients With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03693339
• Other study ID #: STARTER_cMET
• Status: Recruiting
• Phase: Phase 2
• Start date: October 30, 2018
• Est. completion date: June 30, 2022

Study information

• Verified date: October 2018
• Source: Asan Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a phase II, single-arm, open label study under an umbrella trial for NSCLC. This clinical study is targeted for the patients who harbor exon 14 skipping mutation of MET and all patients will be treated with Capmatinib. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 27
• Est. completion date: June 30, 2022
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects with histologically or cytologically confirmed, unresectable stage IIIB/IV NSCLC that carries MET exon 14 skipping alteration by molecular testing, as per NGS and RT PCR.

• ECOG performance status of 0 to 2

• Male or female; = 18

• Subjects with measurable lesion (using RECIST 1.1 criteria)

• Subjects must have archival tissue sample available, collected either at the time of diagnosis of NSCLC or any time since

• Patients who have progressed during or after 1st line or 2nd line therapy prior to the first dose of capmatinib. For patient who have received prior platinum containing adjuvant, neoadjuvant, or definitive chemoradiation for locally advanced disease, those treatments are regarded as 1st line if the progression has occurred < 12 months from last therapy.

Exclusion Criteria:

• Any major operation or irradiation within 4 weeks of baseline disease assessment

• Any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug

• Subjects with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms

• Patients who have received more than 2 lines of prior systemic therapy, which include chemo, immune and targeted therapy

Related Conditions & MeSH terms

• Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Cancer Metastatic
• Lung Neoplasms
• MET Gene Mutation

Intervention

Drug:
• Capmatinib
Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate	ORR is a proportion of patients with a best overall response defined as complete response or partial response by RECIST1.1	At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months]
Secondary	Duration of response	DOR is calculated as the time from the date of the first document of complete remission (CR) or partial remission (PR) to the first documented preogressive disease (PD) or death due to any cause for patients with PR or CR.	At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months
Secondary	Progression-free survival	PFS is defined as time from the first dose of investigational products (IPs) to progression or death due to any cause.; OS is defined as time from the first dose of IPs to death due to any cause.	At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months
Secondary	Overall survival		At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months